Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
25 hedge funds and large institutions have $8.74M invested in Evoke Pharma in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
76% more capital invested
Capital invested by funds: $4.96M → $8.74M (+$3.78M)
64% more call options, than puts
Call options by funds: $1.36M | Put options by funds: $825K
32% more funds holding
Funds holding: 19 → 25 (+6)
0.01% more ownership
Funds ownership: 0.04% → 0.05% (+0.01%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.67M |
| 2 |
Morgan Stanley
New York
|
+$294K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$271K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$101K |
| 5 |
Renaissance Technologies
New York
|
+$98.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$315K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$152K |
| 3 |
Goldman Sachs
New York
|
-$125K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$22K |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$7.02K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Goldman Sachs
New York
| – | -$125K | -244 | Closed |
|
|
27
Acadian Asset Management
Boston,
Massachusetts
| – | -$22K | -43 | Closed |
|
|
OIA
28
Optimum Investment Advisors
Chicago,
Illinois
| – | -$3K | -6 | Closed |
|
EVOK Hedge Fund Activity: Q3 2020 in Review
25 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2020, worth a combined $8.74M — up 76% from $4.96M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new EVOK positions and 3 closed out — a net gain of 6 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.67M. The largest seller was BlackRock, cutting an estimated $315K.
- 25 institutional investors held Evoke Pharma (EVOK) as of Q3 2020, up from 19 in Q2 2020.
- Funds reported $8.74M of Evoke Pharma stock for Q3 2020, up 76% quarter-over-quarter.
- 9 funds opened new Evoke Pharma positions in Q3 2020 and 3 closed out, a net change of +6 holders.
- The largest Evoke Pharma buyer in Q3 2020 was Vanguard Group, an estimated $1.67M added.
- The largest Evoke Pharma seller in Q3 2020 was BlackRock, an estimated $315K sold.
Based on aggregated 13F filings for Q3 2020.